Drug Induced Liver Injury: Is there an Indication for Ursodeoxycholic Acid Use?
DOI:
https://doi.org/10.12970/2308-8044.2021.09.01Keywords:
Drug-induced liver injury, Ursodeoxycholic acid, biliary transporters, vanishing bile duct syndrome, cholestasis.Abstract
Drug induced liver injury (DILI) is one of the most conflicting diagnoses for hepatologists. DILI is defined as an acute or chronic liver injury, manifested by alteration of liver function tests, due to the consumption of medications, herbal or dietary supplements, after excluding other etiologies of liver disease. Several facts contribute to DILI; among them, host related factors, as age, sex, alcohol consumption and underlying chronic diseases; and drug related, as dose, lipophilicity, drug metabolism and interactions. Few treatments for DILI are actually recommended in current guidelines. Ursodeoxycholic acid (UDCA) use for DILI is debated, because of the lack of clinical trials proving its efficacy. Hence, in several case reports UDCA has been used for DILI with good results preventing the progression of the disease and the need of liver transplantation. Small series have also described the resolution or amelioration of DILI with the use of UDCA. Nonetheless, current guidelines do not support its wide use. The aim of this review is to discuss the current knowledge of DILI and the mechanisms of action and facts of the use of UDCA in DILI, making UDCA a promising alternative for the treatment of DILI.References
European Association for the Study of Liver Disease. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019.
Devarbhavi H, Aithal G, Treeprasertuk S, Takikawa H, Mao Y et al. Drug induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 2021. https://doi.org/10.1007/s12072-021-10144-3
Sandhu N, Navarro V. Drug‐Induced Liver In-jury in GI Practice. Hepatology 2020; 4(5): 631-645. https://doi.org/10.1002/hep4.1503
Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, KullakUblick GA, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019; 5(1): 58. https://doi.org/10.1038/s41572-019-0105-0
Guicciarde ME, Gores GJ. Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. Hepatology 2002; 35(4): 971-973. https://doi.org/10.1053/jhep.2002.32931
Kob MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012; 13(7): 8882-8914. https://doi.org/10.3390/ijms13078882
Paumgartner G, Beuers U.Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36(3): 525-531. https://doi.org/10.1053/jhep.2002.36088
Björnsson ES. Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury. Clin Liver Dis 2020; 24(1): 1-10. https://doi.org/10.1016/j.cld.2019.08.002
Leise M, Poterucha JJ, Talwalkar JA. Drug-Induced Liver Injury. Mayo Clin Proc 2014; 89(1): 95-106. https://doi.org/10.1016/j.mayocp.2013.09.016
Bessone F, García-Cortés M, Medina-Caliz I, Hernández N, Parana R et al. Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the Latindili Network. Clin Gastroenterol Hepatol 2021; S1542- 3565(21)00013-6. https://doi.org/10.1016/j.cgh.2021.01.011
Valdivia-Correa B, Gómez-Gutiérrez C, Uribe M, MéndezSánchez N. Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review. Int J Mol Sci 2016; 17(2): 235. https://doi.org/10.3390/ijms17020235
Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66(6): 1154-1164. https://doi.org/10.1136/gutjnl-2016-313369
Bell LN, Chalasani N. Epidemiology of idiosyncratic druginduced liver injury. Semin Liver Dis 2009; 29(4): 337-347. https://doi.org/10.1055/s-0029-1240002
Vega M, Verma M, Beswick D, Bey S, Hossack J et al. The Incidence of Drug- and Herbal and Dietary SupplementInduced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware. Drug Saf 2017; 40(9): 783-787. https://doi.org/10.1007/s40264-017-0547-9
Shen T, Liu Y, Shang J, Xie Q Li J, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology 2019; 156(8): 2230-2241.e11. https://doi.org/10.1053/j.gastro.2019.02.002
Cong W, Xin Q, Gao Y. RE: Incidence and Etiology of DrugInduced Liver Injury in Mainland China. Gastroenterology 2019; 157(5): 1438-1439. https://doi.org/10.1053/j.gastro.2019.05.076
Bessone F, Hernandez N, Lucena MI, Andrade RJ. LATINDILIN. The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. Int J Mol Sci 2016; 17(3): 313. https://doi.org/10.3390/ijms17030313
Teschke R, Andrade RJ. Drug-Induced Liver Injury: Expanding Our Knowledge by Enlarging Population Analysis With Prospective and Scoring Causality Assessment. Gastroenterology 2015; 148 (7): 1271-1273. https://doi.org/10.1053/j.gastro.2015.04.027
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, et al. Features and Outcomes of 899 Patients With DrugInduced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148(7): 1340-1352.e7.
Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011; 53(2): 182-189. https://doi.org/10.1097/MPG.0b013e31821d6cfd
Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology 2017; 152: 1078-1089. https://doi.org/10.1053/j.gastro.2016.12.016
Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8: 29-33. https://doi.org/10.1038/sj.tpj.6500442
Fan WL, Shiao MS, Hui RC, Su SC, Wang CW, et al. HLA Association with Drug-Induced Adverse Reactions. J Immunol Res 2017; 2017: 3186328. https://doi.org/10.1155/2017/3186328
Snijdewind IJM, Smit C, Godfried MH, Nellen JFJB, de Wolf F, Boer K, et al. HCV coinfection, an important risk fac-tor for hepatotoxicity in pregnant women starting antiretroviral therapy. J Infect 2012; 64: 409-416. https://doi.org/10.1016/j.jinf.2011.12.012
Chalasani N, Björnsson E. Risk Factors for Idiosyncratic DrugInduced Liver Injury. Gastroenterology 2010; 138(7): 2246- 2259. https://doi.org/10.1053/j.gastro.2010.04.001
Teschke T, Danan G. Drug-induced idiosyncratic liver injury, cytochrome P450, metabolic risk factors, and lipophilicity: highlights and controversies. Int J Mol Sci 2021,22: 3441. https://doi.org/10.3390/ijms22073441
Stephens C, Andrade RJ. Genetic predisposition to druginduced liver injury. Clin Liver Dis 2020; 24(1): 11-23. https://doi.org/10.1016/j.cld.2019.08.003
Chen M, Suzuki A, Borlak J, Andrade R, Lucena M. Druginduced liver injury: Interactions between drug properties and host factors. Journal of Hepatology 2015; 63: 503-514. https://doi.org/10.1016/j.jhep.2015.04.016
Kaplowitz N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 2013; 58: 15-17. https://doi.org/10.1002/hep.26295
Stieger B. FIC1: another bile salt carrier within the enterohepatic circulation? J Hepatol 2001; 35(4): 522-524. https://doi.org/10.1016/S0168-8278(01)00182-9
Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284(20): 13291-13295. R9000 10200. J Biol Chem 2009; 284(20): 13291-13295. https://doi.org/10.1074/jbc.R900010200
Li M, Huang W, Jie F, Wang M, Zhong Y, et al. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking. Food Chem Toxicol 2019; 133: 110758. https://doi.org/10.1016/j.fct.2019.110758
Pessayre D, Fromenty B, Berson A, Robin MA, Lettéron P et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 2012; 44(1): 34-87. https://doi.org/10.3109/03602532.2011.604086
Wang R, Qi X, Yoshida EM, Méndez-Sánchez N, Teschke R, et al. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol 2018; 12(4): 425-434. https://doi.org/10.1080/17474124.2018.1427581
Nunes V, Mendez-Sanchez N. Impact of Herbal and Dietary Supplements Causing Drug-Induced Liver Injury in Latin America. Clin Liver Dis (Hoboken) 2020; 16(3): 83-86. https://doi.org/10.1002/cld.905
Garcia Cortes M, Robles Diaz M, Stephens C, Aida Ortega Alonso A, Lucena M et al. Drug induced liver injury: an update. Archives of Toxicology 2020; 94(10): 3381-3407. https://doi.org/10.1007/s00204-020-02885-1
Pauli-Magnus C, Meier P. Hepatobiliary Transporters and Drug-Induced Cholestasis. Hepatology 2006, 44(4): 778-787. https://doi.org/10.1002/hep.21359
Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126(1): 322-342. https://doi.org/10.1053/j.gastro.2003.06.005
Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002; 64: 635-661. https://doi.org/10.1146/annurev.physiol.64.082201.100300
Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett 2006; 234(1): 51-61. https://doi.org/10.1016/j.canlet.2005.05.051
Bohan A, Boyer, B. Mechanisms of Hepatic Transport of Drugs: Implications for Cholestatic Drug Reactions Semin Liver Dis 2002; 22(2): 123-136. https://doi.org/10.1055/s-2002-30099
Fontana RJ, Cirulli ET, Gu J, Kleiner D, Ostrov D et al. The role of HLA-A*33: 01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol 2018; 69: 1317-25. J Hepatol 2018; 69(6): 1317-1325. https://doi.org/10.1016/j.jhep.2018.08.004
Hoofnagle J, Björnsson E. Drug-Induced Liver Injury — Types and Phenotypes. N Engl J Med 2019; 381: 264-273. https://doi.org/10.1056/NEJMra1816149
Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13(2): 231-9. https://doi.org/10.1016/S1665-2681(19)30886-5
Teschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics 2021; 11: 458. https://doi.org/10.3390/diagnostics11030458
Bessone F, Hernandez N, Mendizabal M, Sanchez A, Paraná R, ET AL. When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clin Liver Dis (Hoboken) 2019; 4; 13(2): 51-57. https://doi.org/10.1002/cld.778
Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana R, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology 2014; 60(4): 1399-408. https://doi.org/10.1002/hep.27317
Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, Stephens C, Ortega-alomso A, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 2016; 65(3): 532-42. https://doi.org/10.1016/j.jhep.2016.05.003
Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89(6): 806-15. https://doi.org/10.1038/clpt.2011.58
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354(7): 731-9. https://doi.org/10.1056/NEJMra052270
Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147(1): 109-118. https://doi.org/10.1053/j.gastro.2014.03.050
Danan G, Benichou C. Causality assessment of adverse reactions to drugs — I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330. https://doi.org/10.1016/0895-4356(93)90101-6
Naemat Sandhu and Victor Navarro. Drug-Induced Liver Injury in GI Practice. Hepatol Commun 2020; 13; 4(5): 631- 645. https://doi.org/10.1002/hep4.1503
Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, et al. The value of serum aspartate aminotransferase and gammaglutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int 2015; 35(11): 2474-82. https://doi.org/10.1111/liv.12834
Aithal GP, Rawlins MD, Day CP. Accuracy of reports of adverse liver drug reactions in a health region of England. BMJ 1999; 11; 319(7224): 1541. https://doi.org/10.1136/bmj.319.7224.1541
Danan G, Teschke R. RUCAM scale in drug- and herbinduced liver injury: the update. Int J Mol Sci 2016; 17: 14. https://doi.org/10.3390/ijms17010014
García-Cortés M, Stephens C, Lucena MI, FernándezCasta˜ner A, Andrade RJ. Spanish group for the study of drug-induced liver disease. Methods for evaluating causality in drug-induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-691. https://doi.org/10.1016/j.jhep.2011.02.007
Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel) 2020; 7(10): 62. https://doi.org/10.3390/medicines7100062
Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26(3): 664-9. https://doi.org/10.1002/hep.510260319
Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33(1): 123-30. https://doi.org/10.1053/jhep.2001.20645
Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59: 661-70. https://doi.org/10.1002/hep.26709
Licata A, Maida M, Cabibi D, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 2014; 46(12): 1116-20. https://doi.org/10.1016/j.dld.2014.08.040
Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol 2015; 21(24): 7584- 8. https://doi.org/10.3748/wjg.v21.i24.7584
Partridges EV, Medina-Caliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 2014; 106: 246-254.
Raja K, Thung SN, Fiel MI, et al. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 2009; 29(4): 423-8. https://doi.org/10.1055/s-0029-1240011
De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68: 1181-90. https://doi.org/10.1016/j.jhep.2018.01.033
Teschke R, Eickhoff A, Brown AC, Neuman MG, Schulze J. Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted Letter of Support. Int J Mol Sci 2020; 21: 212. https://doi.org/10.3390/ijms21010212
Robles-Díaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkersin DILI: one more step forward. Front Pharmacol 2016; 7: 267. https://doi.org/10.3389/fphar.2016.00267
McGill MR, Jaeschke H. Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients. Expert Opin Drug Metab Toxicol 2014; 10: 1005-17. https://doi.org/10.1517/17425255.2014.920823
Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. The leukocyte integrins. J Biol Chem 2000; 275(31): 23409-12. https://doi.org/10.1074/jbc.R000004200
Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes A, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-64. https://doi.org/10.1136/gutjnl-2016-313369
Bessone F, Hernandez N, Tagle M, Arrese M, Parana R, Méndez-Sánchez N, et al. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol 2021; 24: 100321. https://doi.org/10.1016/j.aohep.2021.100321
Iwaki T, Ishizaki K, Kinoshita S, Tanaka H et al. Protective effects of ursodeoxycholic acid on chenodeoxycholic acidinduced liver injury in hamsters. World J Gastroenterol 2007; 13(37): 5003-8. https://doi.org/10.3748/wjg.v13.i37.5003
Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12(22): 3487-95. https://doi.org/10.3748/wjg.v12.i22.3487
Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease 2000; 108(6): 481-486. https://doi.org/10.1016/S0002-9343(00)00318-1
Ali FEM, Hassanein EHM, Bakr AG, Shoura EAM, El-Gamal DA, et al. Ursodeoxycholic acid abrogates gentamicininduced hepatotoxicity in rats: Role of NF-κB-p65/TNF-α, Bax/Bcl-xl/Caspase-3, and eNOS/iNOS pathways. Life Sci 2020; 254: 117760. https://doi.org/10.1016/j.lfs.2020.117760
Ludwig JM, Zhang Y, Chamulitrat W, Stremmel W, Pathil A. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury. PLoS One 2018; 13(5): e0197836. https://doi.org/10.1371/journal.pone.0197836
Qin CC, Liu YN, Hu Y, Yang Y, Chen Z. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury. World J Gastroenterol 2017; 23(17): 3043-3052. https://doi.org/10.3748/wjg.v23.i17.3043
Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999; 13(8): 979-96. https://doi.org/10.1046/j.1365-2036.1999.00596.x
Amaral J, Viana R, Ramalho R, Steer C, Rodrigues C. Bile acids: regulation of apoptosis by ursodeoxycholic acid. Journal of Lipid Research 2009; 50. https://doi.org/10.1194/jlr.R900011-JLR200
Daniel P. Dissecting the pathways to death. Leukemia 2000; 14(12): 2035-44. https://doi.org/10.1038/sj.leu.2401940
Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87(1): 99- 163. https://doi.org/10.1152/physrev.00013.2006
Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9(3): 459-70. https://doi.org/10.1016/S1097-2765(02)00482-3
Ashkenazi, A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2002; 2(6): 420-30. https://doi.org/10.1038/nrc821
Youle, R., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9(1): 47-59. https://doi.org/10.1038/nrm2308
Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acidinduced apoptosis in primary human hepatocytes. Eur J Clin Invest 2000; 30(3): 203-9. https://doi.org/10.1046/j.1365-2362.2000.00615.x
Castro R, Solá S, Steer C, Rodrigues C. Bile acids as modulators of apoptosis. In Hepatotoxicity: From Genomics to In vitro and in-Vivo Models. S. Sahu, editor. John Wiley & Sons, West Sussex, UK 2007; 391-419. https://doi.org/10.1002/9780470516751.ch15
Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G et al. Role of ursodeoxycholic acid in prevention of methotrexateinduced liver toxicity. Dig Dis Sci 2008; 53(4): 1071-7. https://doi.org/10.1007/s10620-007-9949-3
El-Sherbiny G, Taye A, Abdel-Raheem IT. Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats. Ann Hepatol 2009; 8(2): 134-40. https://doi.org/10.1016/S1665-2681(19)31792-2
Asgarshirazi M, Shariat M, Dalili H, Keihanidoost Z. Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: a Pilot Study. Acta Med Iran 2015; 53(6): 351-5.
Ishizaki K, Iwaki T, Kinoshita S, Koyama M, Fukunari A et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein2 production. Eur J Pharma-col 2008; 578(1): 57-64. https://doi.org/10.1016/j.ejphar.2007.08.031
Buryova H, Chalupsky K, Zbodakova O, Kanchev I, Jirouskova M, et al. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol 2013; 13: 155. https://doi.org/10.1186/1471-230X-13-155
Ito T, Ozaki Y, Son Y, Nishizawa T, Amuro H, et al. Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endo-thelin receptor antagonist bosentan monotherapy: two case reports. J Med Case Rep 2014; 8: 250. https://doi.org/10.1186/1752-1947-8-250
Chen X, Xu J, Zhang C, Yu T, Wang H et al. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. Eur J Pharmacol 2011; 659(1): 53-60. https://doi.org/10.1016/j.ejphar.2011.03.007
Saito Z, Kaneko Y, Kinoshita A, Kurita Y, Odashima K et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect Dis 2016; 16(1): 668. https://doi.org/10.1186/s12879-016-2000-6
Cheng K, Ahsby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017; 9(9): CD000222. https://doi.org/10.1002/14651858.CD000222.pub4
Caballero-Camino FJ, Rivilla I, Herraez E, BrizO, SantosLaso A et al. Synthetic Conjugates of ursodeoxycholic acid inhibit cytogenesis in experimental models of polycystic liver disease. Hepatology 2021; 73(1): 186-203. https://doi.org/10.1002/hep.31216
Mueller M, Thorell A, Claudel T, Jha P, Koefeler H et al. Ursodeoxycholic acid exerts farnesoid X receptorantagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 2015; 62(6): 1398-404. https://doi.org/10.1016/j.jhep.2014.12.034
Glodstein J, Levy C. Novel and emerging therapies for cholestatic liver diseases. Liver Int 2018; 38(9): 1520-1535. https://doi.org/10.1111/liv.13880
Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1: S3-12. https://doi.org/10.1016/S2210-7401(12)70015-3
Cicognani C, Malavolti M, Morselli-Labate AM, Sama C, Barbara L. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 1996; 41(11): 2219-21. https://doi.org/10.1007/BF02071403
Barrio J, Castiella A, Lobo C, Indart A, López P, GarcíaBengoechea M, Cosme A, Arenas JI. Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis. Rev Esp Enferm Dig 1998; 90(7): 523-6.
Malnick SDH, Mahlab K, Borchardt J, Sokolowski N, Attali M. Acute Cholestatic Hepatitis After Exposure to Isoflurane. Ann Pharmacother 2002; 36(2): 261-263. https://doi.org/10.1345/aph.1A009
Zapata-Garrido AJ, Casillas-Romo A, Bosques-Padilla F. Terbinafine hepatotoxicity. A case report and review of literatura. Ann Hepatol 2003; 2(1): 47-51. https://doi.org/10.1016/S1665-2681(19)32159-3
Agca E, Akcay A, Simsek H. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Ann Pharmacother.2004; 38(6): 1088-9. https://doi.org/10.1345/aph.1D420
Valente G, Sanges M, Campione S, Bellevicine C, De Franchis G, et al. Herbal hepatotoxicity: a case of difficult interpretation. Eur Rev Med Pharmacol Sci 2010; 14(10): 865-70. https://doi.org/10.1016/S1590-8658(10)60350-7
Chaabane NB, Safer L, Njim L, Zakhama A, Saffar H. Cholestatic hepatitis related to amoxicillin. Drug Chem Toxicol 2011; 34(4): 357-8. https://doi.org/10.3109/01480545.2010.545067
Mason M, Adeyi O, Fung S, Millar BA. Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. BMJ Case Rep 2014; 2014: bcr2014208117. https://doi.org/10.1136/bcr-2014-208117
Adike A, Smith M, Chervenak A, Vargas HE. Hydroxycutrelated Vanishing Bile Duct Syndrome. Clin Gastroenterol Hepatol 2016; S1542-3565(16)30141-0.
Ikeda E, Watanabe S, Sawada M, Nimomiya J, Dekio I et al. A Case of Liver Dysfunction Requiring Hospital Admission after Taking Oral Itraconazole for the Treatment of Kerion Celsi. Med Mycol J 2017; 58(4): J105-J111. https://doi.org/10.3314/mmj.16-00015
Fernandes CT, Iwbal Um Tighe SP, Ahmed A. KratomInduced Cholestatic Liver Injury and Its Conservative Management. J Investig Med High Impact Case Rep 2019; 7: 2324709619836138. https://doi.org/10.1177/2324709619836138
Elefsiniotis IS, Liatsos GD, Stamelakis D, Moulakakis A.Case report: mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl.Environ Health Perspect 2007; 115(10): 1479-81. https://doi.org/10.1289/ehp.9968
Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD. Granulomatous hepatitis associated with etanercept therapy.J Rheumatol 2008; 35(2): 349-51.
Herrero-Herrero JI, García-Aparicio J. Corticosteroid therapy in a case of severe cholestasic hepatitis associated with amoxicillin-clavulanate. J Med Toxicol 2010; 6(4): 420-3. https://doi.org/10.1007/s13181-010-0019-4
Studniarz M, Czubkowski P, Cielecka-Kuszyk J, Jankowska I, Teisseyre M, et al.Amoxicillin/clavulanic acid-induced cholestatic liver injury after pediatric liver transplantation. Ann Transplant 2012; 17(1): 128-31. https://doi.org/10.12659/AOT.882646
Abenavoli L, Milic N, Beuagrand M. Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report. Ann Hepatol 2013; 12(1): 152-5. https://doi.org/10.1016/S1665-2681(19)31399-7
Piawah S Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer 2019; 5: 17. https://doi.org/10.1038/s41523-019-0112-z
Greca RD, Cunha-Silva M, Costa LBE, Costa JGF, Mazo DFC, et al. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case. Ann Hepatol 2020; 19(1): 107-112. https://doi.org/10.1016/j.aohep.2019.06.010
Díaz-García JD, Córdova-Gallardo J, Torres-Viloria A, Estrada-Hernández R, Torre-Delgadillo A. Drug-induced liver injury secondary to anabolic steroid use. Rev Gastroenterol Mex 2020; 85(1): 92-94. https://doi.org/10.1016/j.rgmxen.2019.01.007
De Jonghe S, Weinstock D, Aligp J, Washington K, Naisbitt D. Biopsy pathology and immunohistochemistry of a case of immune-mediated drug induced liver injury with Atabecestat. Hepatology 2021; 73(1): 452-455. https://doi.org/10.1002/hep.31403
Lang SM, Ortmann J, Rostig S, Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol 2019; 8(1): 89-92. https://doi.org/10.4103/ijmy.ijmy_159_18
Sandhu N, Navarro V. Drug‐Induced Liver In-jury in GI Practice. Hepatology 2020; 4(5): 631-645. https://doi.org/10.1002/hep4.1503
